Skip to main content
Clinical Trials/NCT07657442
NCT07657442Not yet recruitingNot Applicable

A Prospective Study of Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 site in 1 country649 target enrollmentStarted: June 15, 2026Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
649
Locations
1

Study Overview

Brief Summary

This prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.

Detailed Description

Eligible patients with early breast cancer who have undergone breast-conserving surgery will be stratified into a high-risk group or a low-risk group according to the presence or absence of predefined high-risk factors.

Patients in the high-risk group will receive whole-breast irradiation with a simultaneous integrated boost to the tumor bed. The prescribed dose will be 36 Gy in 15 fractions over 3 weeks to the whole breast and 48 Gy in 15 fractions over 3 weeks to the tumor bed.

Patients in the low-risk group will receive partial-breast irradiation. Two hypofractionated schedules may be used: 40.05 Gy in 15 fractions over 3 weeks or 26 Gy in 5 fractions over 1 week.

Patients will be followed during and after radiotherapy to evaluate treatment efficacy, recurrence rates, and acute and late radiation-related toxicities.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Factorial
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ECOG performance status score of 0 to
  • Pathologically confirmed breast cancer, including invasive carcinoma or ductal carcinoma in situ.
  • Clinical stage cT0-2N0M
  • Underwent breast-conserving surgery.
  • Negative surgical margins greater than 2 mm.

Exclusion Criteria

  • Regional lymph node metastasis.
  • Distant metastasis.
  • Bilateral breast cancer.
  • Prior thoracic radiotherapy.
  • Life expectancy of less than 5 years.
  • Lactating or pregnant women.

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials